News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • First Solar shares pulled back from 2026 highs amid headlines about securities suits and tariff uncertainty.
  • Company reported $1.5 billion in free cash flow and maintains a lean balance sheet.
  • Consensus EPS of $16.25 implies a roughly 12.6x P/E multiple.
  • A mid-term long trade targets a rebound to $260 within 45 trading days.
  • Recommended stop-loss for the trade is $185 to limit downside.
  • Valuation and cash flow underpin a buy thesis for First Solar among risk-tolerant investors.

Latest Articles

Chord Energy: Cash Flow Strength Makes Buybacks a Credible Growth Engine

Chord Energy: Cash Flow Strength Makes Buybacks a Credible Growth Engine

Chord Energy's balance sheet and free cash flow profile make a buyback-and-FCF-per-share thesis viable. With free cash flow near $1.19B, modest leverage, and a sub-9x P/E, the stock trades at a valuation that gives management room to repurchase shares while still funding dividends and selective reinvestment. I recommend a position-sized long with a…

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

argenx announced that its Phase 3 ALKIVIA study of VYVGART Hytrulo (efgartigimod) in autoimmune myositis met its primary endpoint, showing significant and sustained improvement in total disease activity score at 52 weeks in the combined population of IMNM and DM patients. This is the first Phase 3 trial demonstrating meaningful clinical benefit in …

Genco Shipping & Trading Limited Issues Open Letter to Shareholders Following Withdrawal by Diana Shipping Inc. of its Offer

Genco Shipping & Trading Limited Issues Open Letter to Shareholders Following Withdrawal by Diana Shipping Inc. of its Offer

Genco Shipping & Trading Limited issued an open letter to shareholders following Diana Shipping Inc.'s withdrawal of its offer to acquire Genco. The Genco board emphasized that Diana's offer undervalued Genco's net asset value, involved misleading tactics, and failed to respect existing shareholder dividends. Genco reaffirmed its comprehensive valu…

Nasdaq and Moomoo host inaugural Investor Day

Nasdaq and Moomoo host inaugural Investor Day

Nasdaq and Moomoo Australia and New Zealand, operating the moomoo trading platform and owned by Futu Holdings Ltd, jointly hosted their first Investor Day in Sydney. The event included expert panels and a keynote by Nasdaq's chief economist discussing macroeconomic forces and the AI trade outlook, aiming to provide Australian retail investors with …

Oil steadies as Hormuz shipping slows and U.S.-Iran talks remain stalled

Oil steadies as Hormuz shipping slows and U.S.-Iran talks remain stalled

Oil prices showed little movement in early trade as vessel traffic through the Strait of Hormuz slowed over the weekend and no agreement materialized to end the U.S.-Iran conflict. Brent ticked up modestly while U.S. crude slipped slightly, leaving markets to weigh supply disruption risks against informal routing and other stopgaps.

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited has completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. The trial treated 350 patients—exceeding the initial target—evaluating pain reduction and improvements in function and quality of life. The therapy has received RMAT designation from…

Nebius Breakout: Pricing Power Rewrites the Growth Story

Nebius Breakout: Pricing Power Rewrites the Growth Story

Nebius (NBIS) just re-priced. Strong net-loss improvement, $236M EBITDA, larger enterprise deals and an asset-light pivot have the market re-assessing growth economics. At a market cap of ~$69.9B the stock is richly valued, but a discrete set of catalysts and technical momentum create a tradeable long setup with defined risk controls over the next …

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

HUTCHMED announced that the global Phase III SAFFRON trial demonstrated that combining ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) significantly improved progression-free and overall survival in patients with MET-driven EGFR-mutated non-small cell lung cancer (NSCLC) after progression on TAGRISSO®. This represents a novel, biomarker-direct…

Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services

Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services

Rocket Lab Corporation announced the successful orbit insertion and commissioning of eight advanced satellite platforms built for MDA Space, part of a 17-satellite build contract supporting Globalstar's replenishment constellation. These satellites enable direct-to-device communications and IoT applications globally. The platforms are built on Rock…

Tariffs, Contracts and Momentum: Why RCAT's Rally Still Has Room to Run

Tariffs, Contracts and Momentum: Why RCAT's Rally Still Has Room to Run

Red Cat (RCAT) has a string of positive government wins and a macro policy tailwind from new tariffs that make a mid-term long trade attractive despite stretched valuation and negative cash flow. Entry at $11.12, stop at $9.25, target $16.50 over a mid-term (45 trading days) horizon. Risk management and close monitoring of program milestones are cr…

TTM Technologies: From Boring PCB Maker to AI-Fueled Growth Play

TTM Technologies: From Boring PCB Maker to AI-Fueled Growth Play

TTM Technologies has pivoted from cyclical PCB manufacturing to being a direct beneficiary of AI infrastructure buildouts. Recent results and Europe-focused acquisitions support revenue acceleration, while valuation still leaves room for upside if growth sustains. This trade idea outlines an actionable entry, stop, and target with clear catalysts a…

Buy Micron Now: KOSPI-Driven Panic Is a Better Entry Than a Warning

Buy Micron Now: KOSPI-Driven Panic Is a Better Entry Than a Warning

Micron (MU) is a buy on pullback. The stock trades at $972.98 after a sector wobble linked to KOSPI weakness. Fundamentals - $26.2B free cash flow, EPS $44.69, ROE 50% and a $1.1T market cap - support a long trade to $1,250 over the next 46-180 trading days. Entry $975, stop $820, target $1,250. Risk is real but manageable with tight sizing.

Church & Dwight: Buy for Volume-Led Growth and Margin Rebound

Church & Dwight: Buy for Volume-Led Growth and Margin Rebound

Church & Dwight ($101.33) offers a pragmatic buy: secular demand in laundry and sexual health categories, recent volume recovery, a conservative balance sheet (debt/equity ~0.52) and improving margins underpin a mid-term swing trade. Entry $101.00, target $110.00, stop $94.00 for a 45-trading-day plan with a medium risk profile.